C-Met targeting in advanced gastric cancer: An open challenge

Cancer Letters

Volumn 365, Issue 1, 2015, Pages 30-36

  Marano, Luigi ^a   Chiari, Rita ^b   Fabozzi, Alessio ^c   De Vita, Ferdinando ^c   Boccardi, Virginia ^d   Roviello, Giandomenico ^e   Petrioli, Roberto ^e   Marrelli, Daniele ^e   Roviello, Franco ^e   Patriti, Alberto ^a  

^a Ospedale San Matteo degli Infermi   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

^e UNIVERSITY OF SIENA   (Italy)

Author keywords

Advanced gastric cancer; Anti c Met drugs; C Met positive gastric cancer; Hepatocyte growth factor; Molecularly targeted agents

Indexed keywords

ABT 700; AMG 337; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; FORETINIB; IRINOTECAN; ONARTUZUMAB; OXALIPLATIN; PLACEBO; RILOTUMUMAB; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; TIVANTINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH CANCER; STOMACH CARCINOGENESIS; UNSPECIFIED SIDE EFFECT; VOMITING; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84930819440     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.05.028     Document Type: Review

References (115)

1. Fock K.M. Review article: the epidemiology and prevention of gastric cancer. Aliment. Pharmacol. Ther 2014, 40:250-260. 10.1111/apt.12814.
2. Piazuelo M.B., Correa P. Gastric cancer: overview. Colomb. Med 2013, 44:192-201.
3. Mahar A.L., Coburn N.G., Singh S., Law C., Helyer L.K. A systematic review of surgery for non-curative gastric cancer. Gastric Cancer 2012, 15(Suppl. 1):S125-S137.
4. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., et al. Global cancer statistics. CA Cancer J. Clin 2011, 61:69-90. 10.3322/caac.20107.
5. Yu S., Yu Y., Zhao N., Cui J., Li W., Liu T. C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis. PLoS ONE 2013, 8:e79137. 10.1371/journal.pone.0079137.
6. Oshima T., Masuda M. Molecular targeted agents for gastric and gastroesophageal junction cancer. Surg. Today 2012, 42:313-327. 10.1007/s00595-011-0065-9.
7. Marano L., Roviello F. The distinctive nature of HER2-positive gastric cancers. Eur. J. Surg. Oncol 2015, 41:271-273. 10.1016/j.ejso.2014.12.007.
8. Qu Y., Dang S., Hou P. Gene methylation in gastric cancer. Clin. Chim. Acta 2013, 424:53-65. 10.1016/j.cca.2013.05.002.
9. Ziogas D., Roukos D. Epigenetics in gastric cancer: challenges for clinical implications. Ann. Surg. Oncol 2009, 16:2077-2078. 10.1245/s10434-009-0472-y.
10. Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci. Publ 2004, 157:327-349.
11. Asaoka Y., Ikenoue T., Koike K. New targeted therapies for gastric cancer. Expert Opin. Investig. Drugs 2011, 20:595-604. 10.1517/13543784.2011.566863.
12. Fornaro L., Lucchesi M., Caparello C., et al. Anti-HER agents in gastric cancer: from bench to bedside. Nat. Rev. Gastroenterol. Hepatol 2011, 8:369-383. 10.1038/nrgastro.2011.81.
13. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697. 10.1016/S0140-6736(10)61121-X.
14. de Mello R.A., Marques A.M., Araújo A. HER2 therapies and gastric cancer: a step forward. World J. Gastroenterol 2013, 19:6165-6169. 10.3748/wjg.v19.i37.6165.
15. Janjigian Y.Y., Werner D., Pauligk C., et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann. Oncol 2012, 23:2656-2662. 10.1093/annonc/mds104.
16. Fuchs C.S., Tomasek J., Yong C.J., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014, 383:31-39.
17. Wilke H., Van Cutsem E., Oh S.C., et al. RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE) [abstract]. J. Clin. Oncol 2014, 32. Abstract LBA7.
18. Yang S., Ngo V.C., Lew G.B., et al. AZD6244 (ARRY-142886) enhances the therapeutic efficacy ofsorafenib in mouse models of gastric cancer. Mol. Cancer Ther 2009, 8:2537-2545. 10.1158/1535-7163.MCT-09-0213.
19. El-Rayes B.F., Zalupski M., Bekai-Saab T., et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann. Oncol 2010, 21:1999-2004. 10.1093/annonc/mdq065.
20. Deng N., Goh L.K., Wang H., et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012, 61:673-684. 10.1136/gutjnl-2011-301839.
21. Okines A.F., Ashley S.E., Cunningham D., et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, Phase II/III REAL-3 Trial. J. Clin. Oncol 2010, 28:3945-3950. 10.1200/JCO.2010.29.2847.
22. Rao S., Starling N., Cunningham D., et al. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br. J. Cancer 2008, 99:868-874. 10.1038/sj.bjc.6604622.
23. Rojo F., Tabernero J., Albanell J., et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J. Clin. Oncol 2006, 24:4309-4316.
24. Dragovich T., McCoy S., Fenoglio-Preiser C.M., et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG0127. J. Clin. Oncol 2006, 24:4922-4927.
25. Han K., Jin J., Maia M., Lowe J., Sersch M.A., Allison D.E. Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial. AAPS J. 2014, 16:1056-1063. 10.1208/s12248-014-9631-6.
26. Doi T., Muro K., Boku N., et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J. Clin. Oncol 2010, 28:1904-1910. 10.1200/JCO.2009.26.2923.
27. Sun W., Powell M., O'Dwyer P.J., et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG5203. J. Clin. Oncol 2010, 28:2947-2951. 10.1200/JCO.2009.27.7988.
28. Peters S., Adjei A.A. MET: a promising anticancer therapeutic target. Nat. Rev. Clin. Oncol 2012, 9:314-326. 10.1038/nrclinonc.2012.71.
29. Nakamura T., Nishizawa T., Hagiya M., Seki T., et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989, 342:440-443.
30. Stoker M., Gherardi E., Perryman M., Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987, 327:239-242.
31. Bottaro D.P., Rubin J.S., Faletto D.L., et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991, 251:802-804.
32. Gherardi E., Youles M.E., Miguel R.N., et al. Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:12039-12044.
33. Gherardi E., Sandin S., Petoukhov M.V., et al. Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:4046-4051.
34. Ponzetto C., Bardelli A., Zhen Z., et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994, 77:261-271.
35. Pelicci G., Giordano S., Zhen Z.X., et al. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene 1995, 10:1631-1638.
36. Fixman E.D., Fournier T.M., Kamikura D.M., et al. Pathways downstream of Shc and Grb2 are required for cell transformation by the tpr-Met oncoprotein. J. Biol. Chem 1996, 271:13116-13122.
37. Boccaccio C., Andò M., Tamagnone L., et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 1998, 391:285-288.
38. Zhang Y.W., Wang L.M., Jove R., et al. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 2002, 21:217-226.
39. Maroun C.R., Holgado-Madruga M., Royal I., et al. The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell. Biol 1999, 19:1784-1799.
40. Weidner K.M., Di Cesare S., Sachs M., et al. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 1996, 384:173-176.
41. Birchmeier C., Birchmeier W., Gherardi E., et al. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol 2003, 4:915-925.
42. Sipeki S., Bander E., Buday L., et al. Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering. Cell. Signal 1999, 11:885-890.
43. Maroun C.R., Naujokas M.A., Holgado-Madruga M., et al. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell. Biol 2000, 20:8513-8525.
44. Comoglio P.M., Boccaccio C., Trusolino L. Interactions between growth factor receptors and adhesion molecules: breaking the rules. Curr. Opin. Cell Biol 2003, 15:565-571.
45. Trusolino L., Bertotti A., Comoglio P.M. A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth. Cell 2001, 107:643-654.
46. Giordano S., Corso S., Conrotto P., et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat. Cell Biol 2002, 4:720-724.
47. Conrotto P., Corso S., Gamberini S., et al. Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 2004, 23:5131-5137.
48. Orian-Rousseau V., Morrison H., Matzke A., et al. Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol. Biol. Cell 2007, 18:76-83.
49. Singleton P.A., Salgia R., Moreno-Vinasco L., et al. CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J. Biol. Chem 2007, 282:30643-30657.
50. Olaku V., Matzke A., Mitchell C., et al. c-Met recruits ICAM-1 as a co-receptor to compensate for the loss of CD44 in the Cd44 null mice. Mol. Biol. Cell 2011, 22:2777-2786.
51. Wang X., DeFrances M.C., Dai Y., et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol. Cell 2002, 9:411-421.
52. Fischer O.M., Giordano S., Comoglio P.M., et al. Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J. Biol. Chem 2004, 279:28970-28978.
53. Jo M., Stolz D.B., Esplen J.E., et al. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J. Biol. Chem 2000, 275:8806-8811.
54. Puri N., Salgia R. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J. Carcinog 2008, 7:9.
55. Bachleitner-Hofmann T., Sun M.Y., Chen C.T., et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol. Cancer Ther 2008, 7:3499-3508.
56. Khoury H., Naujokas M.A., Zuo D., et al. HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol. Biol. Cell 2005, 16:550-561.
57. Benvenuti S., Lazzari L., Arnesano A., et al. Ron kinase transphosphorylation sustains MET oncogene addiction. Cancer Res 2011, 71:1945-1955.
58. Follenzi A., Bakovic S., Gual P., et al. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 2000, 19:3041-3049.
59. Yeh C.Y., Shin S.M., Yeh H.H., et al. Transcriptional activation of the Axl and PDGFR-alpha by c-Met through a ras and Src-independent mechanism in human bladder cancer. BMC Cancer 2011, 11:139.
60. Prat M., Narsimhan R.P., Crepaldi T., et al. The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int. J. Cancer 1991, 49:323-328.
61. Cecchi F., Rabe D.C., Bottaro D.P. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin. Ther. Targets 2012, 16:553-572. 10.1517/14728222.2012.680957.
62. Humphrey P.A., Zhu X., Zarnegar R., et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am. J. Pathol 1995, 147:386-396.
63. Inoue T., Kataoka H., Goto K., Nagaike K., et al. Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci 2004, 95:803-808.
64. Edakuni G., Sasatomi E., Satoh T., Tokunaga O., Miyazaki K. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol. Int 2001, 51:172-178.
65. Tsuta K., Kozu Y., Mimae T., Yoshida A., et al. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J. Thorac. Oncol 2012, 7:331-339. 10.1097/JTO.0b013e318241655f.
66. Go H., Jeon Y.K., Park H.J., Sung S.W., Seo J.W., Chung D.H. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J. Thorac. Oncol 2010, 5:305-313. 10.1097/JTO.0b013e3181ce3d1d.
67. Miyata Y., Sagara Y., Kanda S., Hayashi T., Kanetake H. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin. Hum. Pathol 2009, 40:496-504. 10.1016/j.humpath.2008.09.011.
68. Corso S., Migliore C., Ghiso E., De Rosa G., et al. Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene 2008, 27:684-693.
69. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
70. Hara T., Ooi A., Kobayashi M., Mai M., Yanagihara K., Nakanishi I. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab. Invest 1998, 78:1143-1153.
71. Tsugawa K., Yonemura Y., Hirono Y., et al. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology 1998, 55:475-481.
72. Nakajima M., Sawada H., Yamada Y., et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999, 85:1894-1902.
73. Amemiya H., Kono K., Itakura J., et al. c-Met expression in gastric cancer with liver metastasis. Oncology 2002, 63:286-296.
74. Lee J., Seo J.W., Jun H.J., et al. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol. Rep 2011, 25:1517-1524. 10.3892/or.2011.1219.
75. Toiyama Y., Yasuda H., Saigusa S., et al. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int. J. Cancer 2012, 130:2912-2921. 10.1002/ijc.26330.
76. Huang T.J., Wang J.Y., Lin S.R., Lian S.T., Hsieh J.S. Overexpression of the c-met protooncogene in human gastric carcinoma-correlation to clinical features. Acta Oncol 2001, 40:638-643.
77. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. Met amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
78. Shattuck D.L., Miller J.K., Carraway K.L., Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 2008, 68:1471-1477.
79. Liska D., Chen C.T., Bachleitner-Hofmann T., Christensen J.G., Weiser M.R. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin. Cancer Res 2011, 17:472-482. 10.1158/1078-0432.CCR-10-0568.
80. Agarwal S., Zerillo C., Kolmakova J., et al. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br. J. Cancer 2009, 100:941-949. 10.1038/sj.bjc.6604937.
81. Chen C.T., Kim H., Liska D., Gao S., Christensen J.G., Weiser M.R. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol. Cancer Ther 2012, 11:660-669. 10.1158/1535-7163.MCT-11-0754.
82. Kubicka S., Claas C., Staab S., et al. p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer. Dig. Dis. Sci 2002, 47:114-121.
83. Lu Y., Li X., Liang K., et al. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti EGFR monoclonal antibody cetuximab. Cancer Res 2007, 67:8240-8247.
84. Sierra J.R., Tsao M.S. c-Met as a potential therapeutic target and biomarker in cancer. Ther. Adv. Med. Oncol 2011, 3:S21-S35. 10.1177/1758834011422557.
85. McCarty K.S., Szabo E., Flowers J.L., et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986, 46:4244s-4248s.
86. Cappuzzo F., Hirsch F.R., Rossi E., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl Cancer Inst 2005, 97:643-655.
87. Dziadziuszko R., Wynes M.W., Singh S., et al. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J. Thorac. Oncol 2012, 7:340-347. 10.1097/JTO.0b013e318240ca0d.
88. Shousha S. Oestrogen receptor status of breast carcinoma: Allred/H score conversion table. Histopathology 2008, 53:346-347.
89. Bardelli A., Corso S., Bertotti A., et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013, 3:658-673. 10.1158/2159-8290.CD-12-0558.
90. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol 2007, 25:118-145.
91. Smyth E.C., Sclafani F., Cunningham D. Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther 2014, 7:1001-1014. 10.2147/OTT.S44941.
92. Cao B., Su Y., Oskarsson M., et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:7443-7448.
93. Gao C.F., Xie Q., Zhang Y.W., et al. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor: c-Met-driven models of leiomyosarcoma. Mol. Cancer Ther 2009, 8:2803-2810. 10.1158/1535-7163.MCT-09-0125.
94. Burgess T.L., Sun J., Meyer S., et al. Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol. Cancer Ther 2010, 9:400-409. 10.1158/1535-7163.MCT-09-0824.
95. Iveson T., Donehower R.C., Davidenko I., et al. Safety and efficacy of epirubicin, cis, and capecitabine (ECX) plus rilotumumab (R) as first-line treatment for unresectable locally advanced (LA) or metastatic (M) gastric or esophagogastric junction (EGJ) adenocarcinoma. ESMO 2011, Abstract 6504.
96. Iveson T., Donehower R.C., Davidenko I., et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol 2014, 15:1007-1018. http://dx.doi.org/10.1016/S1470-2045(14)70023-3.
97. ClinicalTrials.gov A phase 3, multicenter, randomized, double-blind, placebo controlled study of rilotumumab (AMG102) with epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in advanced met-positive gastric or gastroesophageal junction adenocarcinoma (NCT01697072) https://clinicaltrials.gov/ct2/show/NCT01697072.
98. ClinicalTrials.gov A phase 3 study of rilotumumab (AMG 102) with cisplatin and capecitabine (CX) as first-line therapy in gastric cancer (RILOMET-2) (NCT02137343) https://clinicaltrials.gov/ct2/show/NCT02137343.
99. Zhu M., Tang R., Doshi S., et al. Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression. Br. J. Cancer 2015, 112:429-437. 10.1038/bjc.2014.649.
100. Merchant M., Ma X., Maun H.R., et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. PNAS 2013, 110:E2987-E2996.
101. Salgia R., Patel P., Bothos J., et al. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin. Cancer Res 2014, 20:1666-1675. 10.1158/1078-0432.CCR-13-2070.
102. Shah M.A., Cho J.Y., Huat I.T.B., et al. Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC). J. Clin. Oncol 2015, 33(Suppl. 3). Abstract 2.
103. ClinicalTrials.gov A study of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative and Met-positive gastroesophageal cancer (MetGastric) (NCT01662869) https://clinicaltrials.gov/ct2/show/NCT01662869?term=MetGastric%26rank=1.
104. Jhawer M.P., Kindler H.L., Wainberg Z.A., et al. Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): interim results of a multicenter phase II study. J. Clin. Oncol 2008, 26:4572. 10.1200/JCO.2007.15.5655.
105. Shah M.A., Wainberg Z.A., Catenacci D.V., et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS ONE 2013, 8:e54014. 10.1371/journal.pone.0054014.
106. Jhawer M.P., Kindler H.L., Wainberg Z., et al. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): interim results of a multicenter phase II study. J. Clin. Oncol 2009, 27. Abstract 14502.
107. Katayama R., Aoyama A., Yamori T., et al. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 2013, 73(10):3087-3096. 10.1158/0008-5472.CAN-12-3256.
108. Basilico C., Pennacchietti S., Vigna E., et al. Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET. Clin. Cancer Res 2013, 19(9):2381-2392. 10.1158/1078-0432.CCR-12-3459.
109. Calles A., Kwiatkowski N., Cammarata B.K., et al. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines. Mol. Oncol 2015, 9:260-269.
110. Yap T.A., Harris D., Barriuso J., et al. Phase I trial to determine the dose range for the c-Met inhibitor ARQ 197 that inhibits c-Met and FAK phosphorylation, when administered by an oral twice-a day schedule. J. Clin. Oncol 2008, 26:3584.
111. Kang Y.K., Muro K., Ryu M.H., et al. A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Invest. New Drugs 2014, 32:355-361. 10.1007/s10637-013-0057-2.
112. Kwak E.L., LoRusso P., Hamid O., et al. Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer. Presented at: 2015 Gastrointestinal Cancers Symposium. J. Clin. Oncol 2015, 33(Suppl. 3). Abstract 1.
113. ClinicalTrials.gov Phase 2 study of AMG 337 in MET amplified gastric/esophageal adenocarcinoma or other solid tumors (NCT02016534) https://clinicaltrials.gov/ct2/show/NCT02016534.
114. ClinicalTrials.gov C-Met inhibitor AMG 337, oxaliplatin, leucovorin calcium, and fluorouracil in treating patients with advanced stomach or esophageal cancer (NCT02344810) https://clinicaltrials.gov/ct2/show/NCT02344810?term=amg337%26rank=1.
115. ClinicalTrials.gov Study of ABT-700 in subjects with advanced solid tumors (NCT01472016) https://clinicaltrials.gov/ct2/show/study/NCT01472016.